title: A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
abstract: The antiestrogen tamoxifen [(Z)-1(p-beta-dimethylamino-ethoxyphenyl)-1,2- diphenylbut-1-ene] is an effective anticancer agent for the treatment of hormone responsive breast cancer. Previous studies have demonstrated that a point mutation in the estrogen receptor (ER) resulted in an alteration of the pharmacology of 4-hydroxytamoxifen, the active metabolite of tamoxifen (Jiang et al, Mol Endocrinol 6:2167-2174, 1992). We have extended our studies to evaluate the effect of a point mutation, a Val substitution for Gly at amino acid 400 in the ligand binding domain of ER, on the pharmacology of other antiestrogens in ER stable transfectants derived from the ER-negative breast cancer cell line MDA-MB-231 CL10A. The compounds were tested with or without estradiol-17 beta (E2) for their effects on cell growth in cells expressing the wild type ER (S30) or the mutant ER (ML alpha 2H) or in control antisense ER transfectant AS23 which does not express ER protein. MCF-7 cells, which express the wild type ER, were also used as a control. The growth of AS23 cells was not affected by any of the compounds at a concentration of 1 microM. E2 stimulated the growth of MCF-7 cells but inhibited the growth of ER transfectants S30 and ML alpha 2H. The ML alpha 2H cells were about 10 to 100-fold less sensitive to E2 and antiestrogens than S30 and MCF-7 cells. Keoxifene, an antiestrogen with a high affinity for the ER, maintained antiestrogenic activities in both ER transfectants and MCF-7 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792.
authors.forename: S Y
authors.initials: SY
authors.lastname: Jiang
authors.forename: C J
authors.initials: CJ
authors.lastname: Parker
authors.forename: V C
authors.initials: VC
authors.lastname: Jordan
mesh_terms: D001943:Breast Neoplasms; D002455:Cell Division / Q000187:drug effects; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008954:Models, Biological; D010880:Piperidines / Q000494:pharmacology*; D017354:Point Mutation / Q000235:genetics*; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000235:genetics*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; C060411:RU 39411; D020849:Raloxifene Hydrochloride; D004958:Estradiol